JP2018504445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504445A5 JP2018504445A5 JP2017541786A JP2017541786A JP2018504445A5 JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5 JP 2017541786 A JP2017541786 A JP 2017541786A JP 2017541786 A JP2017541786 A JP 2017541786A JP 2018504445 A5 JP2018504445 A5 JP 2018504445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- trypsin inhibitor
- oral administration
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 7
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 7
- 239000002753 trypsin inhibitor Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims 4
- 229960001319 parathyroid hormone Drugs 0.000 claims 4
- 239000000199 parathyroid hormone Substances 0.000 claims 4
- 244000068988 Glycine max Species 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 244000045232 Canavalia ensiformis Species 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010064983 Ovomucin Proteins 0.000 claims 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims 1
- 108010049264 Teriparatide Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128296A JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113638P | 2015-02-09 | 2015-02-09 | |
| US201562113673P | 2015-02-09 | 2015-02-09 | |
| US201562113600P | 2015-02-09 | 2015-02-09 | |
| US201562113604P | 2015-02-09 | 2015-02-09 | |
| US201562113629P | 2015-02-09 | 2015-02-09 | |
| US201562113625P | 2015-02-09 | 2015-02-09 | |
| US201562113619P | 2015-02-09 | 2015-02-09 | |
| US62/113,638 | 2015-02-09 | ||
| US62/113,625 | 2015-02-09 | ||
| US62/113,604 | 2015-02-09 | ||
| US62/113,629 | 2015-02-09 | ||
| US62/113,619 | 2015-02-09 | ||
| US62/113,600 | 2015-02-09 | ||
| US62/113,673 | 2015-02-09 | ||
| PCT/IL2016/050151 WO2016128970A1 (en) | 2015-02-09 | 2016-02-09 | Treatment of hypoparathyroidism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128296A Division JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504445A JP2018504445A (ja) | 2018-02-15 |
| JP2018504445A5 true JP2018504445A5 (enExample) | 2019-03-07 |
| JP6925970B2 JP6925970B2 (ja) | 2021-08-25 |
Family
ID=56614456
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
| JP2017541786A Active JP6925970B2 (ja) | 2015-02-09 | 2016-02-09 | 副甲状腺機能低下症の治療 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Active JP7775239B2 (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20180050096A1 (enExample) |
| EP (5) | EP3256113B1 (enExample) |
| JP (6) | JP6925969B2 (enExample) |
| CN (5) | CN107427481A (enExample) |
| CA (3) | CA3011654A1 (enExample) |
| HK (5) | HK1247823A1 (enExample) |
| IL (7) | IL283258B2 (enExample) |
| MX (2) | MX2017010220A (enExample) |
| WO (5) | WO2016128972A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| WO2016128972A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| WO2020183318A1 (en) * | 2019-03-08 | 2020-09-17 | Anya Biopharm Inc. | Oral formulation and treatment of pth analog. |
| JP7792330B2 (ja) * | 2019-09-03 | 2025-12-25 | アムジエン・インコーポレーテツド | Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法 |
| CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
| US12251208B2 (en) * | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| CN114288388B (zh) * | 2022-01-25 | 2023-11-03 | 华中科技大学同济医学院附属协和医院 | 网膜素在制备炎症性肠病治疗药物中的应用 |
| WO2023161937A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2 |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| AU2023226092A1 (en) * | 2022-02-24 | 2024-10-03 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone |
| MX2024010388A (es) * | 2022-02-24 | 2024-09-04 | Entera Bio Ltd | Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos. |
| WO2023161935A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone |
| KR20240152915A (ko) * | 2022-02-24 | 2024-10-22 | 엔테라 바이오 리미티드 | 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 |
| WO2023161938A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide |
| WO2025046590A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations for oral administration of active agents |
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
| CN121398805A (zh) * | 2024-01-05 | 2026-01-23 | 成都国为生物医药有限公司 | 一种地非法林的口服药物组合物 |
| US12466883B1 (en) | 2024-05-13 | 2025-11-11 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
| US20260077020A1 (en) * | 2025-09-26 | 2026-03-19 | Danielle Marie Le Roux | Oral peptide pharmaceutical composition that facilitates enhanced oral absorption |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) * | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| US6875856B2 (en) | 1993-09-24 | 2005-04-05 | Syntro Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
| CN1162917A (zh) * | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2220301C (en) * | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3880093B2 (ja) | 1995-08-08 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 錠剤 |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| CN1228708A (zh) * | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| EA002819B1 (ru) | 1997-05-14 | 2002-10-31 | Авентис Фармасьютикалз Продактс Инк. | Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| AU3240900A (en) * | 1999-02-22 | 2000-09-04 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| EP1163209A4 (en) | 1999-02-26 | 2004-12-29 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| MXPA02004092A (es) | 1999-11-05 | 2003-02-12 | Emisphere Tech Inc | Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos. |
| EP1616561B1 (en) * | 1999-12-28 | 2008-06-25 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| DE60233803D1 (de) * | 2001-08-17 | 2009-11-05 | Novartis Ag | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| BR0214199A (pt) | 2001-11-13 | 2005-01-04 | Emisphere Tech Inc | Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração |
| CA2466863A1 (en) * | 2001-11-29 | 2003-06-05 | Emisphere Technologies, Inc. | Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid |
| CA2469673A1 (en) | 2001-12-19 | 2003-06-26 | Sanwa Kagaku Kenkyusho Co., Ltd. | Controlled release molded product |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| JP2007525472A (ja) * | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| US20060078623A1 (en) | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| JP2008520726A (ja) | 2004-11-19 | 2008-06-19 | スミスクライン・ビーチャム・コーポレイション | 医薬製品 |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| JP5175553B2 (ja) * | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5123471B2 (ja) | 2005-08-18 | 2013-01-23 | 帝人ファーマ株式会社 | 用量調整が容易な製剤 |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| AU2006318815B2 (en) | 2005-11-17 | 2010-08-19 | Novartis Ag | Pharmaceutical composition |
| US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8703821B2 (en) | 2006-04-18 | 2014-04-22 | Emisphere Technologies Inc. | Dialkyl ether delivery agents |
| WO2008072614A1 (ja) * | 2006-12-12 | 2008-06-19 | Horiba Stec, Co., Ltd. | 流量比率制御装置 |
| EP2061440A2 (en) | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| US20100303901A1 (en) | 2007-04-26 | 2010-12-02 | Eyal Shimoni | Oral delivery of proteins and peptides |
| JP2010539096A (ja) * | 2007-09-11 | 2010-12-16 | オラヘルス コーポレーション | 咽喉、食道及び胃の治療のための局所的に活性である成分を放出する接着トローチ |
| WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| CN102123697B (zh) * | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| EP2558106A1 (en) * | 2010-04-16 | 2013-02-20 | Novartis AG | Methods and compositions for improving implant osseointegration |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| EP2747563A4 (en) | 2011-08-26 | 2015-06-24 | Aegis Therapeutics Llc | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS |
| US9402877B2 (en) * | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| WO2013189988A1 (en) * | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| WO2016128972A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| JP7419862B2 (ja) | 2020-02-14 | 2024-01-23 | 株式会社リコー | 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置 |
-
2016
- 2016-02-09 WO PCT/IL2016/050153 patent/WO2016128972A1/en not_active Ceased
- 2016-02-09 US US15/549,442 patent/US20180050096A1/en not_active Abandoned
- 2016-02-09 IL IL283258A patent/IL283258B2/en unknown
- 2016-02-09 CA CA3011654A patent/CA3011654A1/en active Pending
- 2016-02-09 CN CN201680016126.5A patent/CN107427481A/zh active Pending
- 2016-02-09 HK HK18107251.9A patent/HK1247823A1/zh unknown
- 2016-02-09 IL IL292218A patent/IL292218B2/en unknown
- 2016-02-09 US US15/549,418 patent/US20180036234A1/en active Pending
- 2016-02-09 HK HK18107403.6A patent/HK1247843A1/zh unknown
- 2016-02-09 US US15/549,425 patent/US20180028622A1/en active Pending
- 2016-02-09 IL IL253802A patent/IL253802B/en unknown
- 2016-02-09 CN CN202210601969.9A patent/CN114949185A/zh active Pending
- 2016-02-09 EP EP16748831.1A patent/EP3256113B1/en active Active
- 2016-02-09 EP EP16748832.9A patent/EP3256152A4/en active Pending
- 2016-02-09 WO PCT/IL2016/050154 patent/WO2016128973A1/en not_active Ceased
- 2016-02-09 HK HK18107355.4A patent/HK1247835A1/zh unknown
- 2016-02-09 EP EP16748834.5A patent/EP3256114A4/en active Pending
- 2016-02-09 US US15/549,394 patent/US20180036382A1/en active Pending
- 2016-02-09 CN CN202111014609.0A patent/CN113694190B/zh active Active
- 2016-02-09 HK HK18107372.3A patent/HK1247838A1/zh unknown
- 2016-02-09 WO PCT/IL2016/050155 patent/WO2016128974A1/en not_active Ceased
- 2016-02-09 CN CN202111014634.9A patent/CN113730556A/zh active Pending
- 2016-02-09 CA CA2975676A patent/CA2975676A1/en active Pending
- 2016-02-09 WO PCT/IL2016/050151 patent/WO2016128970A1/en not_active Ceased
- 2016-02-09 CA CA2975710A patent/CA2975710C/en active Active
- 2016-02-09 EP EP16748833.7A patent/EP3256153A4/en active Pending
- 2016-02-09 EP EP16748835.2A patent/EP3256149A4/en active Pending
- 2016-02-09 IL IL303216A patent/IL303216A/en unknown
- 2016-02-09 CN CN202111014352.9A patent/CN113713090B/zh active Active
- 2016-02-09 WO PCT/IL2016/050152 patent/WO2016128971A1/en not_active Ceased
- 2016-02-09 MX MX2017010220A patent/MX2017010220A/es unknown
- 2016-02-09 JP JP2017541780A patent/JP6925969B2/ja active Active
- 2016-02-09 US US15/549,436 patent/US10583177B2/en active Active
- 2016-02-09 JP JP2017541786A patent/JP6925970B2/ja active Active
- 2016-02-09 IL IL292417A patent/IL292417B2/en unknown
- 2016-02-09 HK HK18107250.0A patent/HK1247822A1/zh unknown
-
2017
- 2017-08-02 IL IL253804A patent/IL253804B/en unknown
- 2017-08-02 IL IL253803A patent/IL253803B/en active IP Right Grant
- 2017-08-08 MX MX2022014313A patent/MX2022014313A/es unknown
-
2019
- 2019-12-23 US US16/724,400 patent/US12076373B2/en active Active
-
2021
- 2021-08-04 JP JP2021128296A patent/JP2021176914A/ja active Pending
- 2021-08-04 JP JP2021128281A patent/JP7275207B2/ja active Active
-
2023
- 2023-02-06 JP JP2023015960A patent/JP7775239B2/ja active Active
- 2023-05-10 JP JP2023078011A patent/JP2023100920A/ja active Pending
-
2024
- 2024-02-05 US US18/432,185 patent/US20240181020A1/en active Pending
- 2024-08-09 US US18/798,864 patent/US20240398904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504444A5 (ja) | 医薬組成物 | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| JP2015515459A5 (enExample) | ||
| WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
| JP2014129360A5 (enExample) | ||
| RU2015139742A (ru) | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| JP2014507482A5 (enExample) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| MX381895B (es) | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. | |
| JP2008523153A5 (enExample) | ||
| EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| JP2016505613A5 (enExample) | ||
| FR2909284B1 (fr) | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien | |
| HRP20200332T1 (hr) | Modifikator eksenatida i njegova primjena | |
| WO2011089126A3 (en) | Novel retigabine composition | |
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| JP2016513650A5 (enExample) | ||
| WO2016118040A8 (ru) | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| WO2008104852A3 (en) | Pharmaceutical compositions comprising adsorbate of fenofibrate |